MedTrace Logo

Trial Comparing Tisseel as an Adjunct to Traditional Hemostasis After Redo Cardiac Surgery

NCT02360800 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2018-09-18

No results posted yet for this study

Summary

Bleeding after redo cardiac surgery is a common, unresolved and consequences-heavy event as per present day. Tisseel (Baxter inc) sprayed on the already hemostased mediastinum jut before closing seems a promising technique to radically diminish bleeding.

This study aims to verify this efficacy volume in chest drains) and possibly the consensual blood transfusion lessening.

Conditions

Interventions

PROCEDURE

Spray Fibrin Sealant

Baxter Tisseel (Fibrin Sealant) is sprayed in the mediastinum at the end of the operation afetr routine chest hemostasis protocol has been completed, right before closing the chest.

PROCEDURE

Traditional Hemostasis and chest Closure Routine

Routine chest hemostasis and closure protocol (gauzes and inspection till satisfactory according to the surgeon)

Sponsors & Collaborators

  • Cardiochirurgia E.H.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-02
Primary Completion
2018-06-03
Completion
2018-09-16

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02360800 on ClinicalTrials.gov